Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alcon Inc
(NY:
ALC
)
96.09
+0.76 (+0.80%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alcon Inc
< Previous
1
2
3
4
5
6
7
Next >
Alcon Analysts Increase Their Forecasts After Q2 Results
August 22, 2024
Via
Benzinga
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024
August 20, 2024
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
August 20, 2024
From
Alcon Inc. Investors
Via
Business Wire
S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
August 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday
August 20, 2024
Via
Benzinga
Alcon Analysts Increase Their Forecasts Following Q1 Results
May 15, 2024
Via
Benzinga
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
March 12, 2024
Via
Investor Brand Network
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
August 17, 2024
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to...
Via
Talk Markets
US Stocks Trim Gains As Iran Mulls Attack On Israel; Gold, Oil Rally: What's Driving Markets Monday?
August 12, 2024
Wall Street turns negative due to geopolitical risks. Gold rises 1.5% and stocks edge higher. Scotiabank acquires minority stake in KeyCorp.
Via
Benzinga
Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction
August 12, 2024
The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
July 16, 2024
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2?
Via
Benzinga
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
June 24, 2024
From
Alcon Inc. Investors
Via
Business Wire
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q1 2024
May 20, 2024
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Do You Have Your Eye On Vision Care Stocks?
May 20, 2024
For investors seeking stable and growing opportunities, eye care stocks are an attractive option.
Via
Talk Markets
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
May 19, 2024
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news.
Via
Benzinga
Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock
May 15, 2024
Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China.
Via
Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 14, 2024
Via
Benzinga
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
May 14, 2024
Via
Benzinga
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
May 14, 2024
Via
Benzinga
2 Intriguing Medical Stocks To Buy For Steady Growth As Earnings Approach
May 14, 2024
Among the medical sector, Alcon and Prestige Consumer Healthcare are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.
Via
Talk Markets
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
May 13, 2024
From
Alcon Inc. Investors
Via
Business Wire
Alcon Announces Results of 2024 Annual General Meeting
May 08, 2024
From
Alcon Inc. Investors
Via
Business Wire
Star Surgical Shines as U.S. Outlook Improves for 2024
April 16, 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population
Via
MarketBeat
Alcon Publishes Agenda for 2024 Annual General Meeting
April 07, 2024
From
Alcon Inc. Investors
Via
Business Wire
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
March 06, 2024
From
Alcon Inc. Corporate
Via
Business Wire
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
February 27, 2024
From
Alcon Inc. Investors
Via
Business Wire
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
February 09, 2024
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins...
Via
Benzinga
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key'
January 23, 2024
Innovation and digitalization have been in focus among ophthalmology majors.
Via
Benzinga
Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials
January 10, 2024
Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of
Via
Benzinga
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
January 09, 2024
From
Alcon Inc. Investors
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.